Reply to Pascal Mouracade's letter to the editor re: R. Houston Thompson, Tom Atwell, Grant Schmit, et al. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol 2015;67:252-9.

Abstract

We appreciate the interest of Dr. Mouracade regarding our survival analyses [1]. He [2_TD$DIFF]raises [3_TD$DIFF]concerns regarding the [4_TD$DIFF]conclusion [5_TD$DIFF]of our paper[1_TD$DIFF]; however, we believe that each statement in our conclusion is supported by the data and the appropriate methodology. Specifically, in our cohort, we observed that ‘‘recurrence-free survival was similar for PN [partial nephrectomy] and percutaneous ablation patients,’’ that ‘‘metastases-free survival was superior for PN and cryoablation patients,’’ and that ‘‘overall survival was superior after PN,’’ although we qualified this last statement with our opinion that this finding was ‘‘likely because of selection bias.’’ The specific concerns outlined by Mouracade are addressed further.

DOI: 10.1016/j.eururo.2015.05.033

Cite this paper

@article{Thompson2015ReplyTP, title={Reply to Pascal Mouracade's letter to the editor re: R. Houston Thompson, Tom Atwell, Grant Schmit, et al. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol 2015;67:252-9.}, author={R. H. Thompson and Tom Atwell and Grant D. Schmit and Christine M. Lohse and Anil Nicholas Kurup and Adam J. Weisbrod and Sarah P. Psutka and Suzanne Biehn Stewart and Matthew R. Callstrom and John C. Cheville and Stephen Anthony Boorjian and Bradley C. Leibovich}, journal={European urology}, year={2015}, volume={68 4}, pages={e84-5} }